CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Income Statement [Abstract]
Revenues		$ 826.2	$ 762.1	$ 1,602.2	$ 1,479.5
Operating expenses:
Salaries and benefits		235.2	223.2	473.8	438.4
Supplies		215.0	199.7	430.8	388.5
Professional and medical fees		102.1	92.4	197.4	175.0
Lease expense		22.9	22.2	43.7	43.6
Other operating expenses		55.4	45.4	99.0	99.5
Cost of revenues		630.6	582.9	1,244.7	1,145.0
General and administrative expenses		36.1	40.3	72.1	73.5
Depreciation and amortization		40.3	34.8	76.6	68.5
Transaction and integration costs		18.1	19.3	42.8	36.7
Net (gain) loss on disposals, consolidations and deconsolidations		(3.0)	5.3	3.4	6.8
Equity in earnings of unconsolidated affiliates		(5.5)	(4.4)	(11.1)	(7.1)
Litigation settlements		0.0	0.5	2.2	(1.3)
Loss on debt extinguishment		0.0	5.1	0.0	5.1
Other income, net		(2.1)	(6.5)	(2.1)	(8.5)
Total operating expenses		714.5	677.3	1,428.6	1,318.7
Operating income		111.7	84.8	173.6	160.8
Interest expense, net		(67.9)	(51.5)	(130.1)	(98.8)
Income before income taxes		43.8	33.3	43.5	62.0
Income tax benefit (expense)		1.1	(4.9)	1.1	(9.3)
Net income		44.9	28.4	44.6	52.7
Less: Net income attributable to non-controlling interests		(47.4)	(43.9)	(84.8)	(80.6)
Net loss attributable to Surgery Partners, Inc.		$ (2.5)	$ (15.5)	$ (40.2)	$ (27.9)
Net loss per share attributable to common stockholders:
Basic (in USD per share)		$ (0.02)	$ (0.12)	$ (0.32)	$ (0.22)
Diluted (in USD per share)	[1]	$ (0.02)	$ (0.12)	$ (0.32)	$ (0.22)
Weighted average common shares outstanding:
Basic (shares)		126,980	126,134	126,792	126,053
Diluted (shares)	[1]	126,980	126,134	126,792	126,053

[1] The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.